Population pharmacokinetics of meropenem in preterm infants [Популяционная фармакокинетика меропенема у недоношенных новорожденных]

Background. Meropenem, a broad spectrum carbapenem antibiotic, is often used for newborns despite of limited data available on neonatal pharmacokinetics. Due to pharmacokinetic and pharmacodynamic differences as well as to significant changes in the human body related to growth and maturation of organs and systems, direct scaling and dosing extrapolation from adults or older children with adjustment on patient's weight can result in increased risk of toxicity or treatment failures. Aims - to evaluate the pharmacokinetics of meropenem in premature neonates based on therapeutic drug monitoring data in real clinical settings. Materials. Of 53 pre-term neonates included in the pharmacokinetic/pharmacodynamic analysis, in 39 (73.6%) patients, gestational age ranged from 23 to 30 weeks. Population and individual pharmacokinetic parameter values were estimated by the NPAG program from the Pmetrics package based on peak-trough therapeutic drug monitoring. Samples were assayed by high-performance liquid chromatography. One-compartment pharmacokinetic model with zero-order input and first-order elimination was used to fit concentration data and to predict pharmacokinetic parameter (%T > MIC of free drug) for virtual “patients” with simulated fast, moderate and slow meropenem elimination “received” different dosage by minimum inhibitory concentration (MIC) level. Univariate and multivariate regression analysis was used to evaluate the influence of patient's covariates (gestational age, postnatal age, postconceptual age, body weight, creatinine clearance calculated by Schwartz formula, etc) on estimated meropenem pharmacokinetic parameters. Results. The identified population pharmacokinetic parameters of meropenem in pre-term newborns (elimination half-lives T1/2 = 1.93 ± 0.341 h; clearance CL = 0.26 ± 0.085 L/h/kg; volume of distribution V = 0.71 ± 0.22 L/h) were in good agreement with those published in the literature for adults, neonates and older children. Pharmacokinetic/pharmacodynamic modeling demonstrated that a meropenem dosage regimen of 90 mg/kg/day administered using prolonged 3-hour infusion every 8 hours should be considered as potentially effective therapy if nosocomial infections with resistant organisms (MIC ≥ 8 mg/L) are treated. Conclusions. Neonates and especially pre-term neonates have a great pharmacokinetic variability. Meropenem dosing in premature newborns derived from population pharmacokinetic/pharmacodynamic model can partly overcome the variability, but not all pharmacokinetic variability can be explained by covariates in a model. Further personalizing based on Bayesian forecasting approach and a patient's therapeutic drug monitoring data can help to achieve desired pharmacodynamic target. © 2021 Izdatel'stvo Meditsina. All rights reserved.

Номер выпуска
  • 1 Peoples' Friendship University of Russia, 6, Miklukho-Maklaya st., Moscow, 117198, Russian Federation
  • 2 City Clinical Hospital No. 24, Moscow, Russian Federation
Ключевые слова
Meropenem; Population pharmacokinetic/pharmacodynamic modeling; Pre-term newborns; Therapeutic drug monitoring
Дата создания
Дата изменения
Постоянная ссылка

Другие записи

Ershova I.Yu., Krasnopolskaia K.V., Orazov M.R., Lagutina E.V.
Гинекология. Общество с ограниченной ответственностью Медицинское маркетинговое агентство МедиаМедика. Том 23. 2021. С. 386-391
Orazov M.R., Mihaleva L.M., Orekhov R.E., Mullina I.A.
Гинекология. Общество с ограниченной ответственностью Медицинское маркетинговое агентство МедиаМедика. Том 23. 2021. С. 454-458